Interní Med. 2002; 4(8): 374-378

Inhibitory angiotenzin-konvertujícího enzymu v terapii kardiovaskulárních onemocnění - tradiční a nové indikace pro klinické použití lékové skupiny

MUDr. Filip Málek
Kardiocentrum FN Královské Vinohrady, III. lékařská fakulta Univerzity Karlovy, Praha

Keywords: inhibitors of angiotensin-converting enzyme, hypertension, myocardial infarction, chronic heart failure, vascular incidence, vascular brain incidence, diabetes mellitus.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Inhibitory angiotenzin-konvertujícího enzymu v terapii kardiovaskulárních onemocnění - tradiční a nové indikace pro klinické použití lékové skupiny. Interní Med. 2002;4(8):374-378.

Inhibitory angiotenzin-konvertujícího enzymu jsou nejdéle používanou lékovou skupinou, která zasahuje do systému renin-angiotenzin-aldosteron. Používají se v terapii arteriální hypertenze, v léčbě nemocných se srdeční dysfunkcí po infarktu myokardu a v terapii chronického srdečního selhání bez ohledu na etiologii levokomorové dysfunkce.

Pokračující základní a klinický výzkum ukazuje širší možnosti použití těchto léků.

Poznatky z nedávno uveřejněných klinických studií podporují jejich význam v prevenci kardiovaskulárních komplikací u pacientů s vysokým rizikem vaskulárních příhod, dále u nemocných v sekundární prevenci cévních mozkových příhod a širší užití této lékové skupiny u pacientů s hypertenzí provázenou renálním onemocněním a diabetem mellitem.

Článek rekapituluje úlohu angiotenzin-konvertujícího enzymu v organizmu, význam jeho inhibice, farmakologii inhibitorů angiotenzin-konvertujícího enzymu a hlavní klinické indikace. Článek také předkládá stručný pohled na nové možnosti použití této lékové skupiny.

Inhibitors of angiotensin-converting enzyme in the treatment of cardiovascular disease - traditional and new indications to clinical use of this group of medicaments

Inhibitors of angiotensin-converting enzyme are a group of medicaments which have been used for a long time to influence the renin-angiotensin-aldosterone system. Their effect is on patients with arterial hypertension, with heart dysfunction after myocardial infarct and with chronic heart failure, without any consideration of the aetiology of left ventricular dysfunction. The on-going standard and clinical research show a increase in the possibilities for use of this pharmaceutical. The knowledge from the most recent published clinical trials support their importance in the prevention of cardiovascular complications in patients where a risk of cardiovascular incidence is high and in patients where a secondary prevention of vascular brain incidence is important. We can also see an increase of use of this medicament group in patients whose hypertension is connected to renal diseases and diabetes mellitus. The article summarizes the role of the angiotensin-converting enzyme in the organism, the importance of its inhibition, the pharmnacology of inhibitors of this enzyme and the main clinical indications. The article presents a brief outline of new possibilities for the use of this group of medicaments.

Download citation

References

  1. ACE Inhibitor Myocardial Infarction Collaborative Group: Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation 1998; 97: 2202-2212. Go to original source... Go to PubMed...
  2. Brady PA. Angiotensin - Converting Enzyme Inhibitors. In: Murphy JG. Mayo Clinic Cardiology Review. 2 nd Ed. Lippincott Williams @ Wilkins, 1997-2000: 1197-1204.
  3. Cohn JN. From hypertension to heart failure. Eur Heart J 2000 (Suppl), 2: A2-5. Go to original source... Go to PubMed...
  4. Cohn JN. Structural changes in cardiovascular disease. Am J Cardiol 1995; 76 (Suppl E): 34-37. Go to original source...
  5. Ferrari R. Relevance of kinins in the effects of ACE inhibitors. Cardiovasc Lit Monitor Service 2002; 1: 9-14.
  6. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153. Go to original source... Go to PubMed...
  7. Heart Outcomes Prevention Evaluation Study Investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355(9200):253-259. Go to original source...
  8. Horký K, Widimský J, Cífková R. Doporučení diagnostických postupů u arteriální hypertenze. Doporučené postupy v kardiologii, I. část. Česká kardiologická společnost 1998: 59-64.
  9. Hornig B, Drexler H. Endothelial function and bradyinin in humans. Drugs 1997; 5: 42-47. Go to original source... Go to PubMed...
  10. Kannel WB, Castelli WP, Mc Namara PM. Role of blood pressure in the development of congestive heart failure. The Framingham Study. N Engl J Med 1972; 287: 781-787. Go to original source... Go to PubMed...
  11. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041. Go to original source... Go to PubMed...
  12. Rutherford JD, Pfeffer MA, Moye LA, et al. On behalf of SAVE investigators. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. Circulation 1994; 90: 1731-1738. Go to original source... Go to PubMed...
  13. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28: 1328-1428. Go to original source... Go to PubMed...
  14. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302. Go to original source... Go to PubMed...
  15. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429-1435.
  16. Widimský J. Hypertenze: Diagnóza a léčba. Edice praktického lékaře. H?H 1998:11-13, 17-19, 48.
  17. Widimský J. Srdeční selhání. 2. vydání Triton 1998: 9, 10, 13-16.
  18. Yusuf S, Lonn E. Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing trials. Eur Heart J 1998; 19 (Suppl): J36-J44. Go to original source... Go to PubMed...
  19. Yusuf S, Pepine CJ, Farces C, et al. Effect of enalapril on myocardial infarction and unstable angina pectoris in patients with low ejections fractions. Lancet 1992; 340: 1173-1178. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.